AI is not going to eliminate market research jobs in pharma - but it will fundamentally change what those jobs look like, and fast. That's the position of John Shortell, a market research and insights leader with 30+ years of experience, 15 of them focused on oncology, who joined ZoomRx's Decode podcast to make a bet: within five years, AI will impact more than 50% of insights roles in pharma. Not by cutting headcount, he argues, but by elevating what those roles are expected to do.
Shortell has lived through the big data hype cycle, the digital transformation push, and - before either of those - a career spent recording patient, physician, and caregiver conversations on tapes he couldn't fully make use of at the time. He's seen technology waves that fizzled and ones that stuck. His read on AI: this one sticks - and it changes the insights function faster than most people expect.
Asked point-blank whether he'd bet his career on AI disrupting more than half of pharma insights jobs within five years, Shortell didn't hesitate:
"I would expect 50% or more of our jobs to be impacted, but that doesn't mean that I expect them to be eliminated... I don't think insights jobs are going to be eliminated, but role descriptions I truly believe are going to evolve greatly and quickly. This isn't something that's 10 or 15 years from now - this is going to be 12 or 15 months from now."
That distinction - impacted, not eliminated - is the whole thesis. AI isn't positioned to replace the judgment, relationship-building, and strategic framing that insights professionals bring to pharma brand teams. It's positioned to remove the grunt work that's been eating their time for decades: manually stitching together findings across disconnected projects, synthesizing conference literature by hand, or waiting weeks to answer a question the organization technically already has the data to answer.
Shortell has watched pharma chase transformative technology before. Big data, by his account, mostly stalled in the insights function - healthcare data privacy rules limited what could actually be done with it. Digital transformation initiatives absorbed years of investment with comparatively little to show. AI, he argues, is the exception:
"I think it's probably going to be even larger and more impactful than we can envision today, which is polar opposite, I think, of the past experiences."
His conviction isn't theoretical. He describes feeding 6-7 years of personal Peloton workout history and a decade of WhatsApp message history into AI tools and getting instant, accurate analysis that used to require hours in SPSS. If a general-purpose AI tool can do that with personal data on a Tuesday night, the implication for a research archive built specifically for pharma decision-making is hard to ignore.
Shortell doesn't describe a vague productivity boost - he points to four concrete shifts already underway in how insights teams operate, from one-off project work moving toward continuous, always-on intelligence, to insights functions becoming genuine cross-enterprise connectors between medical, sales, and marketing data that today lives in silos.
Decode: AI for Life Sciences and Healthcare is ZoomRx's podcast series on how AI is reshaping market research and commercial strategy in pharma — explore more episodes .
ZoomRx is a life sciences consultancy serving 100+ biopharma companies across the globe, helping insights and brand teams turn research and AI-powered analytics into decisions that move the needle. Learn more at zoomrx.com or contact us.